Skip Navigation


European Heart Journal Advance Access originally published online on September 22, 2006
European Heart Journal 2006 27(20):2376-2377; doi:10.1093/eurheartj/ehl268
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/20/2376    most recent
ehl268v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maurer, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maurer, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Adenosine as an adjunct to reperfusion in myocardial infarction

Gerald Maurer

Department of Cardiology, AKH, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria

Corresponding author. Tel: +43 1 40400 4614; fax: +43 1 40400 4216. E-mail address: gerald.maurer@meduniwien.ac.at

This editorial refers to ‘Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial’{dagger} by R.A. Kloner et al., on page 2400

The first 10% of the full text of this article appears below.

Myocardial reperfusion, be it by thrombolysis or by PCI, is the only intervention that has been shown to reliably decrease both infarct size and mortality. Decreasing the time to initiation of reperfusion treatment and improving the efficacy of recanalizing the occluded coronary artery have had major impact on both myocardial salvage and clinical outcome. In spite of the success of reperfusion therapy, myocardial infarction continues to be associated with substantial morbidity and mortality. The search for additional means of myocardial salvage therefore continues and a multitude of approaches have been tried. One concern is that reperfusion may actually also have deleterious effects,1 including microvascular injury, myocardial stunning, and arrhythmias; reperfusion in and of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial
Robert A. Kloner, Mervyn B. Forman, Raymond J. Gibbons, Allan M. Ross, R. Wayne Alexander, and Gregg W. Stone
EHJ 2006 27: 2400-2405. [Abstract] [FREE Full Text]